Categories: BrainEHRNews

Ibogaine By David Dardashti Leverages Albert Einstein’s Corelation Between Photon Particles and Quantum Electrodynamics

Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators

Einstein

A young and Handsome Albert Einstein

MIAMI, March 15, 2024 (GLOBE NEWSWIRE) — Ibogaine By David Dardashti, a cutting-edge clinic driven by developing unprecedented methodologies, is integrating Albert Einstein’s photoelectric effect to revolutionize the use of solar energy.

Solar Efficiency:

Through the use of natural and renewable energy, individuals will now able to optimize their use of solar energy. In order to create improved solar energy efficiency, Albert Einstein’s photoelectric effect must be accurately utilized. His theory on the wave frequencies of photons and electrons can be used to explain and replicate the energy flow in a more efficient way. Ibogaine By David Dardashti is adapting Einstein’s model of innovative energy efficiency to revolutionize solar energy. Through this breakthrough, radiation generators will be able to access more natural energy through detecting and counting the wavelengths of light flow. This new method of data distribution will account for the trends in quantum electrodynamics that account for the flow of light based on electricity which will lead to higher efficacy in the field of solar energy. The clinic is also striving to implement further methods and techniques to increase the awareness of solar energy efficiency. By using ibogaine to measure electric flow within the brain, Ibogaine By David Dardashti will be able to obtain more in-depth research and understanding of this phenomenon. As Albert Einstein once said, “The world is a dangerous place not because of the dangerous people but because of the people who don’t do anything to stop it.” This innovative clinic is continuously striving to do their part to revolutionize energy efficiency and be part of something bigger.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cd74cc7a-32da-4a24-8f48-95287b8911c3

CONTACT: Gavriel Dardashti
+17869301880
gavriel@ibogaineclinic.com

Staff

Recent Posts

Financière de Tubize – Annual report 2023

FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report…

12 hours ago

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…

12 hours ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…

12 hours ago

NurExone’s Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)…

12 hours ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…

12 hours ago

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction…

12 hours ago